GoodRx Holdings (GDRX) Operating Expenses (2019 - 2026)

GoodRx Holdings has disclosed Operating Expenses across 8 years of filings, most recently posting $180.0 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $180.0 million, changed 0.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $709.8 million (down 0.81% YoY), and the FY2025 annual result was $709.4 million, down 2.36% from the prior year.
• Operating Expenses came in at $180.0 million for Q1 2026 at GoodRx Holdings, up from $172.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $218.3 million in Q3 2023 to a low of $171.4 million in Q2 2023.
• The 5-year median for Operating Expenses is $180.7 million (2024), against an average of $185.8 million.
• Across the five-year window, Operating Expenses climbed 17.85% in 2023 and dropped 19.9% in 2024, its largest moves.
• GoodRx Holdings' Operating Expenses stood at $182.4 million in 2022, then gained by 17.85% to $214.9 million in 2023, then decreased by 16.07% to $180.4 million in 2024, then dropped by 4.6% to $172.1 million in 2025, then grew by 4.59% to $180.0 million in 2026.
• The last three Operating Expenses figures came in at $180.0 million (Q1 2026), $172.1 million (Q4 2025), and $181.4 million (Q3 2025), per Business Quant data.